Physician profile
Bernard H Chang
NPI 1215933197
$4,040.40
in general payments reported to CMS, 2019-2025
23 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $374 · 2021: $596 · 2022: $687 · 2023: $354 · 2024: $604 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.24 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $382.12 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $352.76 | 2019-2025 | Cequa |
| Alcon Vision LLC | $336.79 | 2019-2025 | Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $283.06 | 2020-2024 | Tecnis Iol, Catalys System |
| Biotissue Holdings INC. | $270.87 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $253.35 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $226.41 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $180.11 | 2022-2025 | Scoutpro Osmolarity System, Xiidra, Miebo |
| Rxsight INC | $170.12 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $140.95 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.26 | 2019-2021 | |
| Dompe US, INC. | $126.58 | 2019-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $107.84 | 2019-2021 | |
| Glaukos Corporation | $100.59 | 2020-2025 | Photrexa Viscous and Photrexa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.92 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $85.84 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $72.20 | 2019-2021 | |
| Ocular Therapeutix, INC. | $29.48 | 2022-2024 | Dextenza |
| Thea Pharma INC. | $23.65 | 2023 | Iyuzeh |
| Tearlab Corp | $19.63 | 2024 | Scoutpro Osmolarity System |
| Alcon Research LLC | $15.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.